pibrentasvir

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

for use in combination with glecaprevir (Mavyret) for treatment of chronic hepatitis C

Mechanism of action

inhibitor of the NS5A replication complex

More general terms

Component of

glecaprevir/pibrentasvir (Mavyret)

References

↑ Lowes R FDA OKs 8-Week Mavyret for Hepatitis C Medscape - Aug 03, 2017. http://www.medscape.com/viewarticle/883778

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=58031952

Retrieved from "https://aaushi.info/w/index.php?title=A54473&oldid=956877"

↑ Back to top